{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:03:10Z","timestamp":1771488190891,"version":"3.50.1"},"reference-count":13,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2018,2,1]]},"DOI":"10.1001\/jamapediatrics.2017.4360","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T17:30:54Z","timestamp":1513013454000},"page":"123","source":"Crossref","is-referenced-by-count":27,"title":["Nusinersen for Spinal Muscular Atrophy"],"prefix":"10.1001","volume":"172","author":[{"given":"Vinay","family":"Prasad","sequence":"first","affiliation":[{"name":"Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland"},{"name":"Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland"},{"name":"Center for Health Care Ethics, Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"4","key":"ped170043r5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1001\/jamaoncol.2015.0373","article-title":"Five years of cancer drug approvals: innovation, efficacy, and costs.","volume":"1","author":"Mailankody","year":"2015","journal-title":"JAMA Oncol"},{"key":"ped170043r6","article-title":"Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy","author":"Burgart","journal-title":"JAMA Pediatr"},{"issue":"4","key":"ped170043r9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrclinonc.2016.22","article-title":"Clinical trials: new drug for pancreatic cancer highlights the dual effect of regulatory approvals.","volume":"13","author":"Bates","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"ped170043r12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0002-9343(82)90815-4","article-title":"Randomized versus historical controls for clinical trials.","volume":"72","author":"Sacks","year":"1982","journal-title":"Am J Med"},{"issue":"6","key":"ped170043r13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","article-title":"The high price of anticancer drugs: origins, implications, barriers, solutions.","volume":"14","author":"Prasad","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"ped170043r7","year":"2016"},{"key":"ped170043r1","unstructured":"Xconomy. FidlerB. Biogen sets $750,000 initial price for first-ever spinal atrophy drug. http:\/\/www.xconomy.com\/boston\/2016\/12\/28\/biogen-sets-750000-initial-price-for-first-ever-spinal-atrophy-drug\/. Updated December 29, 2016. Accessed September 27, 2017."},{"key":"ped170043r2","unstructured":"HerperM. For Vertex Pharmaceuticals, can one billion-dollar breakthrough beget another? Forbes. August 8, 2017. https:\/\/www.forbes.com\/sites\/matthewherper\/2017\/08\/08\/vertex-pharmaceuticals-and-the-price-of-inspiration. Accessed September 27, 2017."},{"key":"ped170043r3","unstructured":"TirrellM. New price for muscular dystrophy drug draws criticism. https:\/\/www.cnbc.com\/2017\/05\/08\/new-price-for-muscular-dystrophy-drug-draws-criticism.html. Updated May 8, 2017. Accessed September 27, 2017."},{"key":"ped170043r4","unstructured":"CarrollJ. UPDATED: Alexion wins FDA OK on Strensiq, but startles analysts on price. http:\/\/www.fiercebiotech.com\/regulatory\/updated-alexion-wins-fda-ok-on-strensiq-but-startles-analysts-on-price. Published October 23, 2015. Accessed September 27, 2017."},{"key":"ped170043r8","unstructured":"Center for Drug Evaluation and Research, US Department of Health and Human Services. Application number: 209531Orig1s000: Office Director memo. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/209531Orig1s000ODMemo.pdf. Accessed October 26, 2017."},{"key":"ped170043r10","unstructured":"Center for Drug Evaluation and Research, US Department of Health and Human Services. Application number: 209531Orig1s000: statistical review(s). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/209531Orig1s000StatR.pdf. Accessed October 26, 2017."},{"key":"ped170043r11","unstructured":"SilvermanE. To lower costs, Massachusetts seeks to limit Medicaid drug coverage. Stat. September 28, 2017. https:\/\/www.statnews.com\/pharmalot\/2017\/09\/28\/massachusetts-medicaid-drug-prices\/. Accessed October 26, 2017."}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2665739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T20:33:57Z","timestamp":1532982837000},"score":1,"resource":{"primary":{"URL":"http:\/\/archpedi.jamanetwork.com\/article.aspx?doi=10.1001\/jamapediatrics.2017.4360"}},"subtitle":["Are We Paying Too Much for Too Little?"],"short-title":[],"issued":{"date-parts":[[2018,2,1]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2017.4360","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2,1]]}}}